|1.||Jiang, Shibo: 8 articles (02/2015 - 01/2004)|
|2.||Salgo, Miklos: 6 articles (03/2008 - 05/2003)|
|3.||Moral, M A: 5 articles (12/2010 - 05/2009)|
|4.||Tomillero, A: 5 articles (12/2010 - 05/2009)|
|5.||Lu, Lu: 4 articles (01/2015 - 02/2011)|
|6.||He, Yuxian: 4 articles (03/2013 - 10/2008)|
|7.||Reynes, Jacques: 4 articles (09/2011 - 07/2002)|
|8.||Walmsley, Sharon: 4 articles (09/2008 - 05/2003)|
|9.||Bertasso, Anne: 4 articles (09/2007 - 12/2004)|
|10.||Zhang, Xiaoping: 4 articles (04/2007 - 07/2002)|
|1.||HIV Infections (HIV Infection)
10/01/2003 - "Enfuvirtide, a new treatment for HIV infection."
11/01/2003 - "This study investigated injection site reactions occurring in 7 patients with HIV infection who were receiving enfuvirtide. "
12/01/2011 - "T-20 (also known as enfuvirtide) is a fusion inhibitor peptide known to have some effectiveness in the control of progression of HIV infection by inhibiting the fusion of the HIV envelope with the target cell membrane. "
02/01/2007 - "To optimize enfuvirtide use, consensus recommendations for this purpose have been formulated by 247 physicians attending patients with HIV infection in Spain. "
02/01/2007 - "Enfuvirtide is a high-cost, parenterally administered drug commonly used in late phases of HIV infection, when its efficacy may be compromised. "
06/01/1999 - "Synthetic T20/DP178 peptide is highly efficacious in inhibiting HIV-1 infection in vitro by disrupting the transformation of fusogenic status of viral gp41; thus, it has been proposed for clinical trial. "
09/01/2007 - "Enfuvirtide is an effective treatment for HIV-1 infection in children and adolescents receiving optimized background therapy and has a favorable safety profile. "
11/01/2013 - "ccN28Fd was effective in inhibiting infection by a broad spectrum of primary HIV-1 isolates and enfuvirtide-resistant strains and blocking cell-to-cell HIV-1 transmission. "
01/16/2007 - "Notably, a once-daily dosing regimen for enfuvirtide resulted in a approximately 5-fold weaker inhibition of infection, unmasking the unfavorable pharmacokinetic characteristics of the synthetic peptide in the context of an efficacy trial. "
06/01/2014 - "Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. "
07/01/2009 - "In this study, we have investigated whether the fusion-inhibitor enfuvirtide (ENF) can induce mutations in Rev and if these mutations correlate with the classical ENF resistance gp41 mutations and with viremia and CD4 cell count. "
08/01/2008 - "Breakthrough HIV viremia was associated with worsening symptoms in two patients at 5 and 18 months of enfuvirtide use. "
02/01/2007 - "Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?"
06/01/2008 - "Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations."
12/01/2009 - "A switch to raltegravir in virologically suppressed patients on enfuvirtide is effective in maintaining immunologic and virologic control at 24 weeks but did not result in a change in residual viremia."
|4.||Hemophilia A (Haemophilia)
01/01/2005 - "During the trial, more patients using Fuzeon can also cause severe allergic reactions, and skin reactions at the injection site occurred in almost all patients. "
06/19/2007 - "Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide."
03/04/2005 - "Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction."
11/15/2004 - "Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man."
11/15/2004 - "We report a case of successful, rapid desensitization to enfuvirtide after a hypersensitivity reaction in a man with highly drug-resistant human immunodeficiency virus type 1 infection. "
|2.||Anti-Retroviral Agents (Antiretroviral Agents)
|3.||RNA (Ribonucleic Acid)
|4.||Highly Active Antiretroviral Therapy (HAART)